Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk , after the company lost its first mover ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...